메뉴 건너뛰기




Volumn 27, Issue 10, 2013, Pages 567-571

Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; CT P 13; CT P13; GASTROINTESTINAL AGENT; INFLIXIMAB; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

EID: 84885599208     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/327120     Document Type: Article
Times cited : (30)

References (32)
  • 1
    • 84868366831 scopus 로고    scopus 로고
    • Health canada/biotecanada summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), ottawa: May 14, 2012
    • Kay J, Feagan BG, Guirguis MS, et al. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa: May 14, 2012. Biologicals 2012;40:517-27.
    • (2012) Biologicals , vol.40 , pp. 517-527
    • Kay, J.1    Feagan, B.G.2    Guirguis, M.S.3
  • 3
    • 84856392773 scopus 로고    scopus 로고
    • Biosimilars: Current perspectives and future implications
    • Misra M. Biosimilars: Current perspectives and future implications. Indian J Pharmacol 2012;44:12-4.
    • (2012) Indian J Pharmacol , vol.44 , pp. 12-14
    • Misra, M.1
  • 5
    • 84867849193 scopus 로고    scopus 로고
    • Subsequent entry biologics/biosimilars: A viewpoint from canada
    • Russell AS, Ahluwalla V, Barnabe C, et al. Subsequent entry biologics/biosimilars: A viewpoint from Canada. Clin Rheumatol 2012;31:1289-92.
    • (2012) Clin Rheumatol , vol.31 , pp. 1289-1292
    • Russell, A.S.1    Ahluwalla, V.2    Barnabe, C.3
  • 6
    • 82155188444 scopus 로고    scopus 로고
    • Biosimilars: A regulatory perspective from america
    • Kay J. Biosimilars: A regulatory perspective from America. Arthritis Res Ther 2011;13:112.
    • (2011) Arthritis Res Ther , vol.13 , pp. 112
    • Kay, J.1
  • 11
    • 80053575082 scopus 로고    scopus 로고
    • The first subsequent entry biologic authorized for market in canada: The story of omnitrope, a recombinant human growth hormone
    • Klein AV. The first subsequent entry biologic authorized for market in Canada: The story of Omnitrope, a recombinant human growth hormone. Biologicals 2011;39:278-81.
    • (2011) Biologicals , vol.39 , pp. 278-281
    • Klein, A.V.1
  • 13
    • 0035895071 scopus 로고    scopus 로고
    • Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin
    • Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001;98:3626-34.
    • (2001) Blood , vol.98 , pp. 3626-3634
    • Skibeli, V.1    Nissen-Lie, G.2    Torjesen, P.3
  • 14
    • 21444442363 scopus 로고    scopus 로고
    • Biosimilar epoetins: An analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins
    • DOI 10.1592/phco.2005.25.7.954
    • Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: An analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005;25:954-62. (Pubitemid 40917928)
    • (2005) Pharmacotherapy , vol.25 , Issue.7 , pp. 954-962
    • Combe, C.1    Tredree, R.L.2    Schellekens, H.3
  • 15
    • 58149388237 scopus 로고    scopus 로고
    • Effects of adalimumab maintenance therapy on health-related quality of life of patients with crohn's disease: Patient-reported outcomes of the charm trial
    • Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008;103:3132-41.
    • (2008) Am J Gastroenterol , vol.103 , pp. 3132-3141
    • Loftus, E.V.1    Feagan, B.G.2    Colombel, J.F.3
  • 16
    • 55449098725 scopus 로고    scopus 로고
    • Effects of adalimumab therapy on incidence of hospitalization and surgery in crohn's disease: Results from the charm study
    • Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: Results from the CHARM study. Gastroenterology 2008;135:1493-9.
    • (2008) Gastroenterology , vol.135 , pp. 1493-1499
    • Feagan, B.G.1    Panaccione, R.2    Sandborn, W.J.3
  • 17
    • 70349418632 scopus 로고    scopus 로고
    • Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab
    • Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-60.
    • (2009) Gastroenterology , vol.137 , pp. 1250-1260
    • Sandborn, W.J.1    Rutgeerts, P.2    Feagan, B.G.3
  • 18
    • 77950988234 scopus 로고    scopus 로고
    • Infliximab azathioprine or combination therapy for crohn's disease
    • Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
    • (2010) N Engl J Med , vol.362 , pp. 1383-1395
    • Colombel, J.F.1    Sandborn, W.J.2    Reinisch, W.3
  • 19
    • 84868514758 scopus 로고    scopus 로고
    • Inflammatory bowel disease: A canadian burden of illness review
    • Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: A Canadian burden of illness review. Can J Gastroenterol 2012;26:811-7.
    • (2012) Can J Gastroenterol , vol.26 , pp. 811-817
    • Rocchi, A.1    Benchimol, E.I.2    Bernstein, C.N.3
  • 20
    • 84885593430 scopus 로고    scopus 로고
    • Green Shield Canada. Accessed March 14
    • Green Shield Canada. https://www.cutrust.com/employee/downloads/Benefits/ drugforms/ Drug%20Special%20Authorization%20Request%20Form%20for%20TNF%20Antagonists%20and %20Similar%20Biologics%20(2012-02).pdf(Accessed March 14, 2013).
    • (2013)
  • 21
    • 84873736952 scopus 로고    scopus 로고
    • A randomized, double-blind, phase 3 study demonstrates clinical equivalence of ct-p13 to infliximab when co-Administered with methotrexate in patients with active rheumatoid arthritis
    • Yoo D, Miranda P, Piotrowski M. A randomized, double-blind, phase 3 study demonstrates clinical equivalence of CT-P13 to infliximab when co-Administered with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2012;71:359.
    • (2012) Ann Rheum Dis , vol.71 , pp. 359
    • Yoo, D.1    Miranda, P.2    Piotrowski, M.3
  • 22
    • 84867753437 scopus 로고    scopus 로고
    • A randomized, double-blind, phase 1 study demonstrates equivalence in pharmacokinetics, safety, and efficacy of ct-p13 and infliximab in patients with ankylosing spondylitis
    • Park W, Hrycaj P, Kovalenko V. A randomized, double-blind, phase 1 study demonstrates equivalence in pharmacokinetics, safety, and efficacy of CT-P13 and infliximab in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:111.
    • (2012) Ann Rheum Dis , vol.71 , pp. 111
    • Park, W.1    Hrycaj, P.2    Kovalenko, V.3
  • 23
    • 84864300619 scopus 로고    scopus 로고
    • Inflammatory bowel disease in asia: A systematic review
    • Prideaux L, Kamm MA, De Cruz PP, et al. Inflammatory bowel disease in Asia: A systematic review. J Gastroenterol Hepatol 2012;27:1266-80.
    • (2012) J Gastroenterol Hepatol , vol.27 , pp. 1266-1280
    • Prideaux, L.1    Kamm, M.A.2    De Cruz, P.P.3
  • 25
    • 0037434552 scopus 로고    scopus 로고
    • Influence of immunogenicity on the long-Term efficacy of infliximab in crohn's disease
    • Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-Term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
    • (2003) N Engl J Med , vol.348 , pp. 601-668
    • Baert, F.1    Noman, M.2    Vermeire, S.3
  • 26
    • 70350130547 scopus 로고    scopus 로고
    • Influence of trough serum levels and immunogenicity on long-Term outcome of adalimumab therapy in crohn's disease
    • Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-Term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.
    • (2009) Gastroenterology , vol.137 , pp. 1628-1640
    • Karmiris, K.1    Paintaud, G.2    Noman, M.3
  • 27
    • 34548130215 scopus 로고    scopus 로고
    • Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
    • DOI 10.1136/gut.2006.099978
    • Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-31. (Pubitemid 47300423)
    • (2007) Gut , vol.56 , Issue.9 , pp. 1226-1231
    • Vermeire, S.1    Noman, M.2    Van Assche, G.3    Baert, F.4    D'Haens, G.5    Rutgeerts, P.6
  • 28
    • 33749432435 scopus 로고    scopus 로고
    • Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for crohn's disease
    • DOI 10.1016/j.cgh.2006.06.025, PII S154235650600677X
    • Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54. (Pubitemid 44512213)
    • (2006) Clinical Gastroenterology and Hepatology , vol.4 , Issue.10 , pp. 1248-1254
    • Maser, E.A.1    Villela, R.2    Silverberg, M.S.3    Greenberg, G.R.4
  • 29
    • 73449088039 scopus 로고    scopus 로고
    • Trough serum infliximab: A predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
    • Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: A predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut;59:49-54.
    • Gut , vol.59 , pp. 49-54
    • Seow, C.H.1    Newman, A.2    Irwin, S.P.3
  • 30
    • 80455139421 scopus 로고    scopus 로고
    • Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: The uc success trial
    • Abst
    • Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: The UC Success Trial. Gastroenterology 2011;140:A-202. (Abst)
    • (2011) Gastroenterology , vol.140
    • Panaccione, R.1    Ghosh, S.2    Middleton, S.3
  • 31
    • 47549097069 scopus 로고    scopus 로고
    • Epoetin-Associated pure red cell aplasia: Past, present, and future considerations
    • McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-Associated pure red cell aplasia: Past, present, and future considerations. Transfusion 2008;48:1754-62.
    • (2008) Transfusion , vol.48 , pp. 1754-1962
    • McKoy, J.M.1    Stonecash, R.E.2    Cournoyer, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.